Wolverine Legal Status, FDA 503A Category, and Compounding Access

Where access stands today — and where it is heading

The Wolverine legal status question has a clear present-tense answer and a genuinely open near-term one, and the honest thing is to lead with both. Today, both of the blend's components are restricted for pharmacy compounding. But that status is not settled: it is under active review at the U.S. Food and Drug Administration, and the agency has a meeting on the calendar in 2026 to reconsider exactly these peptides. So the direction of travel matters as much as the current rule.

Here is the current fact, stated plainly. The FDA placed BPC-157 in "Category 2" — bulk drug substances that may present significant safety risks — effective with the September 29, 2023 update to its list of nominated substances ^[12]. It did the same for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," in the same update ^[12]. Category 2 substances are not covered by the FDA's enforcement-discretion policy for traditional (503A) compounding, which is why compounded access to both peptides is currently restricted ^[13].

And here is the momentum. Both BPC-157 and TB-500 are on the published agenda of the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[14]. That is a scheduled discussion of substances under active evaluation — not a decision, not a reclassification, and not a guaranteed outcome. But it is a real, dated step in a process that could expand access, and it is happening to both constituents of this blend at once.

FDA 503A Status of the Blend

What is the FDA 503A status of Wolverine?

The blend has no 503A status of its own — it is not a single substance — so the question resolves to its two ingredients, and both sit in the same place. Under the U.S. Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may use a bulk drug substance under Section 503A only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list ^[13]. Neither BPC-157 nor TB-500 meets those conditions today; both are in Category 2 ^[12].

There is no component carve-out here, and that is worth being explicit about. BPC-157 and TB-500 (the thymosin beta-4 fragment, LKKTETQ) are both Category 2, both currently outside the 503A enforcement-discretion policy, and both on the single July 23-24, 2026 PCAC agenda as candidates for the bulks list ^[12][14]. Whatever happens to one constituent's status is being considered alongside the other's, in the same scheduled review.

It is also worth separating two things the FDA treats separately: whether a finished drug is approved, and whether a bulk substance may be used in compounding. Neither peptide is an FDA-approved drug, and that approval question is distinct from the compounding-eligibility question above ^[13].

BPC-157 and Compounding Pharmacy Access

Can you get BPC-157 from a compounding pharmacy?

Under current FDA policy, BPC-157 is not eligible for routine 503A compounding. It is a Category 2 bulk substance — identified as one that may present significant safety risks, with the FDA citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization — and Category 2 substances fall outside the enforcement-discretion policy that lets pharmacies compound with substances still under evaluation ^[12][13].

That status is what the July 2026 PCAC meeting will revisit: BPC-157 (listed as "BPC-157 (free base)" and "BPC-157 acetate") is on the agenda as a substance being considered for inclusion on the 503A bulks list ^[14]. Until and unless the FDA acts, the current restriction stands. We describe the rule, not a way around it; the compounding pharmacy access pathway below is general information about how lawful access works, not a route to a restricted substance.

How lawful compounded access works, in general

This section is general information about how legally compounded peptide access is structured in the U.S. — not medical or legal advice, and not specific to any pharmacy, clinic, or provider. We name no vendors and give no dosing.

A legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[21]. Telehealth can serve as the front-end channel for that evaluation — it is one route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances may be compounded ^[21].

The prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office and batch use, sourced from an FDA-registered 503B outsourcing facility ^[21]. The decisive caveat sits at the end of that pathway: a compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules. Ingredients the FDA has flagged for significant safety risks — which currently includes both BPC-157 and TB-500 — are not eligible for routine 503A compounding while that status stands ^[13][21]. So the pathway is real and well-defined, but for these two peptides the ingredient-eligibility step is exactly where it currently stops.

Is the Wolverine Blend Legal?

"Is Wolverine legal" has no single yes-or-no answer, because the blend is two unapproved research peptides, not a finished drug. Neither BPC-157 nor TB-500 is FDA-approved, and the blend has no approved indication anywhere ^[12]. Both constituents are currently Category 2 bulk substances, so neither is eligible for routine 503A compounding today, though both are under the scheduled July 23-24, 2026 FDA review ^[12][14]. This is general regulatory information, not legal advice.